{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:28:42Z","timestamp":1792682922583,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.\n                  <\/jats:p>","DOI":"10.1038\/s41408-025-01414-6","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:49:10Z","timestamp":1764323350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Razzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-0325","authenticated-orcid":false,"given":"Utkarsh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Sannareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2643-7840","authenticated-orcid":false,"given":"Mariola A.","family":"Vazquez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-4856","authenticated-orcid":false,"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-6590","authenticated-orcid":false,"given":"Mahmoud R.","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5462-4991","authenticated-orcid":false,"given":"Alex","family":"Lieberman-Cribbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-085X","authenticated-orcid":false,"given":"Masooma S.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2461","authenticated-orcid":false,"given":"Kelley","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"DeJarnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Ouchveridze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2518","authenticated-orcid":false,"given":"Sandra P.","family":"Susanibar-Adaniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-2723","authenticated-orcid":false,"given":"Daniel","family":"Schrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Eberwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4292","authenticated-orcid":false,"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"1414_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"1414_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1\u201320.","journal-title":"Leukemia"},{"key":"1414_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk N, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194:496\u2013507.","journal-title":"Br J Haematol"},{"key":"1414_CR4","doi-asserted-by":"publisher","first-page":"S546","DOI":"10.1016\/S2152-2650(24)01664-1","volume":"24","author":"LJ Costa","year":"2024","unstructured":"Costa LJ, Bahlis NJ, Usmani SZ, van de Donk NWCJ, Nooka AK, Perrot A, et al. MM-328 efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM) with high-risk (HR) features: a subgroup analysis from the phase 1\/2 MajesTEC-1 study. Clin Lymphoma Myeloma Leuk. 2024;24:S546\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1414_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1414_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00730-5","volume":"12","author":"R Jim\u00e9nez-Segura","year":"2022","unstructured":"Jim\u00e9nez-Segura R, Rosi\u00f1ol L, Cibeira MT, Fern\u00e1ndez de Larrea C, Tovar N, Rodr\u00edguez-Lobato LG, et al. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J. 2022;12:135.","journal-title":"Blood Cancer J"},{"key":"1414_CR7","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"1414_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fern\u00e1ndez de Larrea","year":"2021","unstructured":"Fern\u00e1ndez de Larrea C, Kyle R, Rosi\u00f1ol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11:192.","journal-title":"Blood Cancer J"},{"key":"1414_CR9","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1414_CR10","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1097\/RLU.0000000000004588","volume":"48","author":"B Jamet","year":"2023","unstructured":"Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bod\u00e9r\u00e9 F, Touzeau C. 2-[18 F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma. Clin Nucl Med. 2023;48:e230\u20131.","journal-title":"Clin Nucl Med"},{"key":"1414_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41375-023-01824-0","volume":"37","author":"AM Leipold","year":"2023","unstructured":"Leipold AM, Werner RA, D\u00fcll J, Jung P, John M, Stanojkovska E, et al. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. Leukemia. 2023;37:650\u20138.","journal-title":"Leukemia"},{"key":"1414_CR12","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3324\/haematol.2024.286233","volume":"109","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Beltran S, Goldfinger M, Janakiram M, Kalbi D, Verma A, et al. Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma. Haematologica. 2024;109:2368\u201371.","journal-title":"Haematologica"},{"key":"1414_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1414_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"1414_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397.","journal-title":"Blood"},{"key":"1414_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"D Dima","year":"2024","unstructured":"Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J. 2024;14:90.","journal-title":"Blood Cancer J"},{"key":"1414_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17:42.","journal-title":"J Hematol Oncol"},{"key":"1414_CR18","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjh.19505","volume":"205","author":"B Ferment","year":"2024","unstructured":"Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, et al. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): a real-world IFM study from the DESCAR-T registry. Br J Haematol. 2024;205:990\u20138.","journal-title":"Br J Haematol"},{"key":"1414_CR19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:1665\u201375.","journal-title":"J Clin Oncol"},{"key":"1414_CR20","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1414_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/blood-2024-204341","volume":"144","author":"KH Maclachlan","year":"2024","unstructured":"Maclachlan KH, Garces J-J, Shekarkhand T, Rajeeve S, Hashmi H, Hassoun H, et al. Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease. Blood. 2024;144:248.","journal-title":"Blood"},{"key":"1414_CR22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38:1323\u201333.","journal-title":"Leukemia"},{"key":"1414_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01208-2","volume":"15","author":"N Bingham","year":"2025","unstructured":"Bingham N, Shah J, Wong D, Lim SL, Bergin K, Kalff A, et al. Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma. Blood Cancer J. 2025;15:5.","journal-title":"Blood Cancer J"},{"key":"1414_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01081-z","volume":"14","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, et al. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14:122.","journal-title":"Blood Cancer J"},{"key":"1414_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","volume":"7","author":"EL Smith","year":"2019","unstructured":"Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, et al. BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunol Res. 2019;7:1047\u201353.","journal-title":"Cancer Immunol Res"},{"key":"1414_CR26","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","volume":"4","author":"RK Das","year":"2020","unstructured":"Das RK, O\u2019Connor RS, Grupp SA, Barrett DM. Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv. 2020;4:4653\u201364.","journal-title":"Blood Adv"},{"key":"1414_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das RK, Vernau L, Grupp SA, Barrett DM. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9:492\u20139.","journal-title":"Cancer Discov"},{"key":"1414_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14:63.","journal-title":"Blood Cancer J"},{"key":"1414_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","volume":"2","author":"EW Meermeier","year":"2021","unstructured":"Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021;2:354\u201369.","journal-title":"Blood Cancer Discov"},{"key":"1414_CR30","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood-2024-203778","volume":"144","author":"T Chalopin","year":"2024","unstructured":"Chalopin T, Demarquette H, Pieragostini A, Sonntag C, Jacquet C, van De Wyngaert Z, et al. Debulking conventional chemotherapy before treatment by anti-BCMA bispecific antibody in extramedullary and\/or high tumor burden relapsed\/refractory multiple myeloma. Blood. 2024;144:1986.","journal-title":"Blood"},{"key":"1414_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392:138\u201349.","journal-title":"N Engl J Med"},{"key":"1414_CR32","doi-asserted-by":"crossref","unstructured":"Zhou X, Fl\u00fcchter P, Nickel K, Meckel K, Messerschmidt J, B\u00f6ckle D, et al. Carfilzomib based treatment strategies in the management of relapsed\/refractory multiple myeloma with extramedullary disease. Cancers. 2020;12:1035.","DOI":"10.3390\/cancers12041035"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01414-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01414-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01414-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:05:00Z","timestamp":1768165500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01414-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01414-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AA reports Advisory role for Karyopharm, BMS, Sanofi, Johnson & Johnson, Pfizer, and research funding from Abbvie, Adaptive Biotech, K36-therapeutics, for Johnson & Johnson, Regeneron Pharmaceuticals. DD reports Advisory role for Karyopharm. BR reports advisory role for Johnson & Johnson. CJF reports consulting: Johnson & Johnson; Research: Johnson & Johnson, Regeneron; ownership of publicly traded stock: Affimed. RB reports consulting: Adaptive Biotech, BMS, Caribou Biosciences, Genentech, Gilead, Johnson & Johnson, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; Research: Abbvie, BMS, Johnson & Johnson, Novartis, Pack Health, Prothena, Sanofi. JK reports consulting: GPCR, Johnson & Johnson, Prothena, Legend Biotech; research: Prothena, Ascentage, Johnson & Johnson, Karyopharm, GPCR. JAD reports consultancy for BMS, Johnson & Johnson; speaker\u2019s bureau for Johnson & Johnson. MRG advisory board to BMS and Arcellx. KJ reports advisory board consultant for Johnson & Johnson, Pfizer, and BioLineRx. FA reports advisor role and speaker for BMS, Celgene, Caribou biosciences; research funding from Allogene Therapeutic, Celgene, GlaxoSmithKline, Bristol Myers Squibb, and Caribou Biosciences. LS reports consulting for Johnson & Johnson, BMS, Novartis. AFG-C reports advisory board, speaker bureau for Sanofi, Johnson & Johnson, Pfizer; Advisory board for BMS, and sperak bureau for Amgen and Cellectar. SPS-A reports research from Johnson & Johnson, and consultancy for Sanofi and Johnson & Johnson. AJP reports consulting from Karyopharm, Capvision. HH reports consulting for Johnson & Johnson; speaker bureaus for Johnson & Johnson, Karyopharm. LM reports advisory board with Legend Biotech and BioLineRx. GK reports consulting: BMS, Arcellx, Sanofi, Johnson & Johnson, Cellectar, Pfizer, Kedrion; Research: BMS, Johnson & Johnson, Abbvie. JPM reports honoraria: Kite\/scitmentum, a Gilead company, AlloVir, Nektar, Sana Biotechnology, BMA, Sanofi, Novartis, CRISPR Therapeutics, CARGO Therapeutics, Autolus, Legend Biotech. Consulting or Advisory Role: Kite, a Gilead company, Juno Therapeutics, AlloVir, Magenta Therapeutics, EcoR1 Capital, CRISPR Therapeutics, and Speakers\u2019 Bureau: Kite\/Gilead. Research Funding: Novartis (Inst), Fresenius Biotech (Inst), Astellas Pharma (Inst), Bellicum Pharmaceuticals (Inst), Novartis (Inst), Gamida Cell (Inst), Pluristem Therapeutics (Inst), Kite, a Gilead company (Inst), AlloVir (Inst). AR reports Consulting from Johnson & Johnson, BMS, Sanofi, Karyopharm and research support from Johnson & Johnson, Caribou, BMS. OC reports consulting from Legend Biotech Inc, BMS, and Johnson & Johnson. SR reports advisory board from Pfizer, Prothena Biosciences, and kite, and research from Nexcella Inc, Poseida and Johnson & Johnson. YL reports consulting from Johnson & Johnson, Legend, Celgene, Sanofi, BMS, Pfizer, Regeneron, Genentech, NexImmune, Caribou; research funding from Johnson & Johnson, Celgene, BMS. SA reports research funding: GSK, Amgen, Karyopharm; honoraria: Johnson & Johnson. DS reports consulting from Sanofi, Johnson & Johnson, Pfizer, BMS, GlaxoSmithKline, Legend Biotech, Bioline, AstraZeneca, Arcellx, Abbvie, Genentech, Opna Bio, and research from Pfizer. PMV reports consultancy for Abbvie, AstraZeneca; BMS, Karyopharm, Lava Therapeutics, Sanofi; Regeneron, Johnson & Johnson, GSK; research funding: Abbvie, GSK, Johnson & Johnson, Regeneron. SR reports honoraria from Johnson & Johnson, BMS, Genentech, Karyopharm Therapeutics, MJH LifeSciences; steering committees: Gracell Therapeutics, BMS; research support: Johnson & Johnson, BMS, C4 Therapeutics, Gracell Therapeutics, Heidelberg Pharma; consulting: Genentech, Johnson & Johnson, BMS, Karyopharm Therapeutics. FLL reports Scientific Advisory Role\/Consulting Fees: A2, Adaptive Biotechnologies, Adaptimmune, Allogene, Amgen, Astra-Zeneca, Bluebird Bio, BMS, Calibr, Caribou, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Miltenyi, Novartis, Sana, Pfizer, Poseida. Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee. Research Contracts or Grants to my Institution for Service: 2SeventyBio (Institutional), Allogene (Institutional), BMS (Institutional), Incyte (Institutional), Kite Pharma (Institutional), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke), Mark Foundation, National Cancer Institute, Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. Education or Editorial Activity: Aptitude Health, ASH, ASTCT, Clinical Care Options Oncology, Society for Immunotherapy of Cancer. ALG reports research funding: Johnson & Johnson, Novartis, Tmunity, CRISPR Therapeutics; consulting: Johnson & Johnson, Gracell, BMS, GSK, Regeneron, Abbvie, Smart Immune; IDMC membership for Johnson & Johnson. SS reports research: Magenta Therapeutics, BMS, Allogene, Johnson & Johnson, Novartis, Abbvie; Advisory Board\/Consultancy: BMS, Johnson & Johnson, Sanofi, Oncopeptides, Takeda, Regeneron, Abbvie, Pfizer, BiolineRx, Legend, Kite. KKP reports advisory\/Consultancy from Johnson and Johnson, BMS, Legend Bioteh, Pfizer, Takeda, Sanofi, Oricel, Kite, Arcellx, Caribou Sciences, Novartis, Takeda, Regeneron, Poseida. DKH reports research funding from BMS, Johnson & Johnson, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting or advisory role for BMS, Johnson & Johnson, Legend Biotech, Pfizer, Kite Pharma, AstraZeneca, and Karyopharm. AJC reports consulting: Abbvie, Adaptive, BMS, HopeAI, Johnson & Johnson, Sebia, Sanofi; Research: Abbvie, Adaptive Biotechnologies, Caelum, Harpoon, Nektar, BMS, Johnson & Johnson, Sanofi, OpnaBio, IgM Biosciences, Regeneron. LDAJ reports consulting: Johnson & Johnson, Celgene, BMS, Amgen, GSK, AbbVie, Beigene, Cellectar, Sanofi, Prothena. Research: BMS, Celgene,\n                      Johnson & Johnson\n                      , Abbvie. HCL reports consulting: BMS, Pfizer, Johnson & Johnson, Regeneron, GlaxoSmithKline, Sanofi, Abbvie, Takeda Pharmaceuticals, Allogene Therapeutics, Menarini, Alexion Pharmaceuticals; research funding: Amgen, Bristol Myers Squibb, Johnson & Johnson, GSK, Regeneron, Takeda Pharmaceuticals. The rest of the authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was conducted in accordance with the principles of the International Conference on Harmonization (ICH) and Good Clinical Practice (GCP) guidelines. The study protocol was reviewed and approved by the Institutional Review Board or ethics committee at each participating institution (MD Anderson Cancer Center, Houston, TX; Fred Hutchinson Cancer Center, Seattle, WA; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; Medical University of South Carolina, Charleston, SC; Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Moffitt Cancer Center, Tampa, FL; Mount Sinai School of Medicine, New York, NY; Stanford University, Palo Alto, CA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC; University of Kansas Medical Center, Kansas City, KS; Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Duke University Cancer Institute, Durham, NC; and Mayo Clinic, Division of Hematology, Rochester, MN; all in the USA). Given the retrospective nature of the study, informed consent was waived or not required by the respective IRBs in accordance with applicable federal regulations and institutional policies. All data were handled in compliance with relevant privacy and confidentiality guidelines. All authors had access to the data and contributed to the analysis and interpretation of the results. The authors confirm the accuracy and completeness of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"12"}}